Upadacitinib

Phase 1Active

1 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Juvenile Idiopathic Arthritis (JIA)

Conditions

Juvenile Idiopathic Arthritis (JIA)

Trial Timeline

Jun 24, 2019 → May 1, 2027

NCT ID

NCT03725007

About Upadacitinib

Upadacitinib is a phase 1 stage product being developed by AbbVie for Juvenile Idiopathic Arthritis (JIA). The current trial status is active. This product is registered under clinical trial identifier NCT03725007. Target conditions include Juvenile Idiopathic Arthritis (JIA).

What happened to similar drugs?

0 of 20 similar drugs in Juvenile Idiopathic Arthritis (JIA) were approved

Approved (0) Terminated (2) Active (18)

🔄PLX-200 + PlaceboPolaryx TherapeuticsPhase 3

🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3

🔄MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3

🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3

🔄AdalimumabEisaiPhase 3

🔄AbataceptOno PharmaceuticalPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04159597	Pre-clinical	Active	—	—	Crohn Disease
NCT06332534	Phase 3	Recruiting	Jul 26, 2024	Dec 1, 2034	Crohn's Disease
NCT06773403	Approved	Recruiting	Apr 9, 2024	Jan 1, 2026	Prurigo Nodularis
NCT05782907	Phase 3	Active	Nov 6, 2023	Oct 1, 2033	Ulcerative Colitis
NCT05507580	Approved	Completed	May 29, 2023	Aug 15, 2024	Atopic Dermatitis
NCT05094128	Pre-clinical	Recruiting	Nov 22, 2021	Jun 1, 2026	Axial Spondylarthritis (r-axSpA)
NCT04195698	Phase 3	Completed	Jan 15, 2020	Sep 11, 2023	Atopic Dermatitis
NCT03725007	Phase 1	Active	Jun 24, 2019	May 1, 2027	Juvenile Idiopathic Arthritis (JIA)

Competing Products

20 competing products in Juvenile Idiopathic Arthritis (JIA)

See all competitors

Product	Company	Stage	Hype Score
PLX-200 + Placebo	Polaryx Therapeutics	Phase 3	37
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
Adalimumab	Eisai	Phase 3	40
Abatacept	Ono Pharmaceutical	Phase 3	40
Ixekizumab + Adalimumab	Eli Lilly	Phase 3	44
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib	Eli Lilly	Phase 3	47
Baricitinib + Tocilizumab	Eli Lilly	Phase 3	47
adalimumab + Methotrexate	AbbVie	Pre-clinical	26
Upadacitinib + Tocilizumab	AbbVie	Phase 3	47
Adalimumab + Risankizumab	AbbVie	Phase 3	47
Adalimumab	AbbVie	Phase 3	40
naproxen + esomeprazole	AstraZeneca	Phase 1	29
Alendronate (Fosamax)	Merck	Pre-clinical	26
canakinumab	Novartis	Phase 3	40
Secukinumab	Novartis	Phase 1	36
ACZ885 150 mg (Canakinumab)	Novartis	Phase 3	40